DEF: Repligen Corporation Announces 2025 Annual Meeting and Proxy Statement

Repligen Corporation releases its 2025 proxy statement, outlining key proposals for the upcoming annual meeting, including director elections, auditor ratification, executive compensation, and a liability amendment.

Summary

• Repligen Corporation has released its proxy statement for the 2025 Annual Meeting of Shareholders, scheduled for May 15, 2025.
• Shareholders will vote on the election of ten directors, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on executive compensation, and an amendment to the company's certificate of incorporation to limit officer liability.
• The Board of Directors recommends voting in favor of all proposals.
• The meeting will be held virtually at www.virtualshareholdermeeting.com/RGEN2025.
• The record date for determining eligible voters is March 24, 2025.
• The notice of internet availability of proxy materials was first sent on or about April 4, 2025.
• In 2024, Repligen achieved its defined goals in five areas: growing the funnel of opportunities, expanding presence in new modalities, launching nine innovative new products, integrating Metenova into the Fluid Management business, and expanding margin and implementing cost controls.
• Full year reported revenue was approximately $634.4 million, including $14.8 million of acquisition revenue and $11.5 million of COVID-related revenue.
• The company completed the acquisition of Tantti Laboratory, Inc. in December 2024.
• As of December 31, 2024, Repligen maintained a strong balance sheet with cash and cash equivalents of approximately $757 million.
• In December 2024, Repligen published its 2023 Sustainability Report.
• The company's executive compensation program is designed to align executive interests with those of shareholders.
• The Compensation Committee determined that the Company achieved the adjusted revenue metric at 105% of target level and achieved the adjusted EPS metric at a level 83% of the target level and, therefore, the achievement of the Company Objectives was determined to be 94.2% of target.
• The Compensation Committee has assessed the attainment of these objectives by Mr. Loeillot, Mr. Garland, Mr. Bylund, Mr. Kuriyel and Ms. Gebski for 2024 and determined achievement of the Individual Performance Objectives for such NEOs.
• The company's CEO Pay Ratio was approximately 69:1.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both achievements and areas where performance fell short. The overall tone is positive, emphasizing growth and strategic initiatives, but acknowledges challenges in meeting certain financial targets.

Positives

• The Board recommends voting 'FOR' all proposals.
• Repligen achieved $634.4 million in revenue in 2024 and completed the acquisition of Tantti Laboratory, Inc.
• The company's cash and cash equivalents totaled approximately $757 million as of December 31, 2024.
• The company's executive compensation program is designed to align executive interests with those of shareholders.

Negatives

• PSU awards were not earned due to not achieving the organic revenue growth goal or Adjusted ROIC goal for the PSU awards.

Risks

• The nature of the role of directors and officers often requires them to make decisions on crucial matters.
• Frequently, directors and officers must make decisions in response to time-sensitive opportunities and challenges, which can create substantial risk of investigations, claims, actions, suits, or proceedings seeking to impose liability on the basis of hindsight, especially in the current litigious environment and regardless of merit.

Future Outlook

The company is well-positioned as it enters 2025, with strong orders from CDMOs and for Equipment.

Management Comments

• The Sales organization including our extended Key Account Management team did excellent work to generate new leads and improve visibility of our entire bioprocessing technology portfolio at our Top 25 Pharmaceutical and CDMO accounts.
• Our strategy of developing and launching tailored solutions for the various new modalities has been very successful, and with the expected growth CAGR of greater than 30% for this part of the market, we are ideally positioned to continue capturing market share.
• Disciplined cost control was an area of focus for the organization in 2024, and our operations team did an excellent job implementing roof top consolidations and additional restructuring actions.
• Margin expansion continues to be a priority for the team.
• We believe the breadth of talent and experience Repligen has today will enable us to become further fit for growth.

Industry Context

Repligen operates in the bioprocessing industry, providing biopharmaceutical manufacturers with technologies to improve drug development and manufacturing. The company's focus on new modalities like gene therapy, cell therapy, and mRNA-based biologics aligns with the growing demand for these therapies.

Comparison to Industry Standards

• The 2024 peer group was composed of comparable companies in the bioprocessing, life sciences research tools and health care supplies industries with median revenues of $912.0 million, as compared to the Company’s 2024 revenue of $634.4 million.
• Repligen's peer group includes companies such as Avid Bioservices, Insulet Corporation, NeoGenomics, Azenta, Maravai LifeSciences Holdings, NovaCure Limited, Bio-Rad Laboratories, Medpace Holdings, 10x Genomics, Bio-Techne Corporation, Mesa Laboratories, Quanterix Corporation, Bruker Corporation, Natera, Waters Corporation, Halozyme Therapeutics, and Neogen Corporation.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Decisions on director elections, executive compensation, and corporate governance matters.
• Employees: Changes in leadership and compensation structures.
• Customers: Continued focus on innovation and product development.
• Suppliers: Emphasis on sustainability and responsible supply chain practices.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Shareholders on May 15, 2025.
• The company is preparing to formally launch the MixOne line of single-use mixers combined with our proprietary single use bags in the first half of 2025.

Key Dates

Keywords

Proxy statement, Annual meeting, Shareholders, Directors, Executive compensation, Auditor, Repligen, Governance